The surgical instrument reduces tissue adhesion and allows a clear view of the coagulation for efficient preparation.
JENA, Germany , Oct. 10, 2022 /PRNewswire/ -- ZEISS Medical Technology announced that it has received 510(k) clearance from the FDA for MTLawton™. These new disposable bipolar forceps are made from a special copper-base alloy and potentially reduce tissue adhesion and subsequent charring during dissection of tissue. Thanks to the extended shaft, the forceps also reduce visual restrictions in the surgical field and help surgeons to be efficient during electrosurgical procedures.
By working closely with users, ZEISS Medical Technology succeeds in developing solutions that help doctors treat their patients in the best possible way. The development of the new bipolar forceps from ZEISS is based on close collaboration with Michael T. Lawton , one of the world's leading neurosurgeons. "The MTLawton Disposable Bipolar Forceps are a real advance in electrosurgery over aluminum forceps. Our copper-base alloy has superior thermal conduction to improve cautery-based hemostasis and reduce tissue adhesion," emphasizes Michael T. Lawton , MD, President and CEO, Chair, Department of Neurosurgery, Barrow Neurological Institute, Phoenix/Arizona (USA). "I take these MTLawton bipolars into battle with all my difficult arteriovenous malformations, and they give me a noticeable advantage."
Advantages for hemostatic treatment in minimally invasive procedures
During minimally invasive surgery, bipolar forceps are used, among other things, for hemostasis and tissue separation. When coagulating tissue, the high heat at the tips of the electrosurgical instruments can cause the instruments to stick to the tissue. MTLawton from ZEISS takes non-stick technology to a whole new level by introducing our bipolar forceps made of a special copper-base alloy. The improved material conducts heat away from the silver-plated tips faster. Thereby, tissue adhesion and charring are potentially reduced.
Optimum support during surgical procedures
In neurosurgery, visualization and surgical instruments need to go hand-in-hand such that critical structures are not covered. With its elegant shape and extended working length, the MTLawton allows a clear view of the cauterization area – even in narrow and deep cavities. Thanks to the copper-based material, MTLawton from ZEISS is also robust and enables surgeons to handle tissue more efficiently.
"With the acquisition of Kogent Surgical in April 2022 , ZEISS has expanded its range of surgical solutions for microsurgery. We are pleased to be able to introduce the first surgical instrument from this acquisition to the market with FDA approval for MTLawton," says Dr. Markus Weber , CEO of Carl Zeiss Meditec.
ZEISS will present MTLawton along with other solutions for neurosurgery at the Congress of Neurological Surgeons (CNS) in San Francisco from October 10-12, 2022 .
You can find more information about electrosurgical instruments from ZEISS here: www.zeiss.com/microsurgical-instruments
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development.
Contact for investors Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Tel.: +49 3641 220 116 Mail: investors.meditec@zeiss.com
Contact for the press Petra Rettenmaier Head of Marketing Communications Visualization Carl Zeiss Meditec AG Tel.: +49 3641 220 331 Mail: press.med@zeiss.com
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,531 employees worldwide, the Group generated revenue of €1,646.8m in fiscal year 2020/21 (to 30 September).
The Group's head office is located in Jena, Germany , and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA , Japan , Spain and France . The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China , strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med
View original content to download multimedia:https://www.prnewswire.com/news-releases/zeiss-receives-fda-clearance-for-mtlawton--a-new-generation-of-bipolar-forceps-for-electrosurgery-301644965.html
SOURCE Carl Zeiss Meditec AG
Joe Biden committed to taking specific actions related to cannabis in his 2020 presidential campaign. On Thursday, President Biden announced pardons for all individuals with prior federal convictions for simple possession of marijuana. Biden also directed Attorney General Merrick Garland and Secretary of Health and Human Services (HHS) Xavier Becerra to review how marijuana is scheduled under the Controlled Substances Act.
MARKET PULSE Shares of Albireo Pharma Inc. (ALBO) gained 10.4% in premarket trading on Tuesday after the company said it is seeking Food and Drug Administration approval to use its medication Bylvay as a treatment for Alagille syndrome, a rare inherited disorder that can result in liver damage.
Select Medical (SEM) joins forces with UPMC to open its third inpatient rehabilitation hospital in Central Pennsylvania to better address the region's post-acute care needs.
If there is, it's wrong too -- at least when applied to the stock market. As a case in point, here are three top biotech stocks that are defying the bear market. Few stocks in any sector have outperformed Vertex Pharmaceuticals (NASDAQ: VRTX) in 2022.
(Bloomberg) -- GSK Plc is free to hire a top dealmaker from AstraZeneca Plc after reaching an agreement with its rival, which had sued to block the sharing of sensitive information.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketThis Is What 7% Mortgages Will Do to the Housing MarketIt’s Official: The Fed’s in the RedThe Most Powerful Buyers in Treasuries Are All Bailing at OnceScreening Procedure Fails to Prevent Colon Cancer Deaths in Large StudyChris Sheldon w
Recently, Biogen Inc (NASDAQ: BIIB) and Eisai Co (OTC: ESALY) announced encouraging data from the most-watched Alzheimer's therapies in the clinic. Lecanemab cleared accumulations in the brain of beta-amyloid, sticky protein fragments that researchers have long suspected contribute to Alzheimer's. Citing physicians and neurology researchers, Wall Street Journal reported that the drug's benefit to patients might be limited. They said the reduction of cognitive decline that patients experienced wa
The British drugmaker is reducing production of its Covid-19 vaccine and betting on new therapies for other conditions.
Vertex's (VRTX) CF sales are primarily being driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
Medicare’s open enrollment period arrives predictably each fall, blanketing beneficiaries in advertisements. From Oct. 15 through Dec. 7, the roughly 65 million Medicare beneficiaries can pick a new Medicare Part D drug plan, a new Medicare Advantage plan, or switch from original Medicare into a Medicare Advantage plan or vice versa.
Although Biogen and Eisai’s lecanemab cleared plaque from patients’ brains, researchers say the benefits may be limited.
15 those already on Medicare can make changes to their coverage as needed. This is known as the Medicare annual enrollment period. Read: Sticking with your Medicare plan this open enrollment season?
"He's struggling with speaking," she said, getting choked up. "I don't know. I just know, keep us in your prayers."
Illustration by Luis G. Rendon/The Daily BeastAs the wave of COVID infections from the highly-contagious BA.5 subvariant finally subsided back in late July, new subvariants were already competing for dominance—and the opportunity to drive the next wave of infections.A little over two months later, epidemiologists are close to naming a winner. In the United Kingdom, infections from a highly mutated subvariant called BQ.1.1 are doubling every week—a rate of growth that far exceeds other leading su
A fire department official said 25 children and eight staff members were evacuated from the Happy Smiles Learning Center in Allentown, Pa. Victims were taken to local hospitals in stable condition.
ORLANDO, Fla. — The Food and Drug Administration on Monday responded to the results of Florida Surgeon General Joseph Ladapo’s analysis of COVID-19 data that he says point to a risk for some men who get the shot. Ladapo recommended against COVID-19 mRNA vaccines for men ages 18-39, a decision that contradicts the Centers for Disease Control and Prevention’s vaccine guidance and has invited ...
Local medical experts are bracing for a worse-than-usual flu season are urging most residents to minimize their risk by getting a flu shot.
The company hopes the drug, sotatercept, will help make up for revenue it will lose when the patent on a blockbuster cancer therapeutic expires at the end of this decade.
Vaginal discharge is often misunderstood, but it plays a key role in keeping the vagina healthy.
Merck stock jumped Monday after a drug it acquired for billions scored a "must-win" in patients with a rare blood pressure condition.